AGEN

[D&Data]

 :oAntigenics kidney-cancer trial fails to meet goals

from 5,11------to 2.85 $...

[wrangler]

Put order in @1.98 will update later when order is filled

[wrangler]

Order got filled @1.98 Reason for buy is I just like the chart showing MACD is in uptrend almost hitting centerline and is aboust to move across 32 day MA. Seems to be comming back up after recent drop. Will update chart latter today after hours to show the reasons.
Goodluck trading to all

Come on NMKT

[setravis]

Watch for retrace...dip...pullback.

52wk Range: 1.38 - 3.41
Volume: 3,566,215
Avg Vol (3m): 188,068

Technicals
Percentage Gainer

Last Price Quote is:
66.52%above 13-day MA
101.51%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $72.43 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/09/2007
Last Analyst Rating: Sell

[setravis]

"AGEN" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                        
All history on a stock pick in 1 thread is awesome.                                      
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.                   
Thank You....and good luck with all your trades....make some $$$     

[Livana]

17% down on pretty high volume... should we be worried??

[Livana]

I completely messed up my buy order...  Anyway, I'm in at 3.2499.  Hopefully, we closed over that today!!

[Livana]

Well, well, AGEN isn't disappointing so far.
Opened at 3.17, high at 3.60. I'm looking at 3.51 right now. A little under 1 hour to go before closing.

I have a sell order at 4.90, which is at the 127.2% extension.  Below is the very simplistic chart I use to figure this out.
I got in right below the 1st pullback of 3.28, and am looking at an extension to 4.90.  I might be a little too optimistic.

[setravis]

Bouncing in the neighborhood of a
50% Fibonacci retracement.


52wk Range: 1.38 - 4.60
Volume: 1,039,181
Avg Vol (3m): 304,387

Technicals
Percentage Gainer

Last Price Quote is:
23.61%above 13-day MA
55.08%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $72.43 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/09/2007
Last Analyst Rating: Sell

[Livana]

Wow! AGEN is on Fire today... My sell order kicked at 4.90.

As I speak, the stock is up 45% at 5.30 with 3.8M in volume

[nexta]

http://www.biospace.com/news_company.aspx?CompanyID=138204

[setravis]

The news came out and the stock started to rock.......


Antigenics reports positive data from Oncophage trial
SAN FRANCISCO (MarketWatch)

11:13am 05/21/2007
3.23, +0.69, +27.2%) said Monday additional follow-up data from a Phase III study of the company's investigational therapeutic kidney cancer vaccine Oncophage showed that in a substantial subset of patients at intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival. The Anaheim, Calif.-based company also said the analysis showed that for intermediate-risk patients there was a trend towards improved overall survival, the study's secondary endpoint. Antigenics shares jumped 33% to $3.38 in Monday morning trade.

[setravis]

ANAHEIM, Calif., May 21, 2007 (BUSINESS WIRE) -- Antigenics Inc. (AGEN, Trade) today announced additional follow-up data on the company's Phase 3 investigational therapeutic cancer vaccine Oncophage(R) (vitespen). The end-of-study results, which reflect an additional 17 months' data collection, showed that in a substantial subset of patients (n = 362) at intermediate risk for disease recurrence, Oncophage demonstrated a clinically significant improvement in recurrence-free survival (RFS) of approximately 45 percent (P less than 0.01; hazard ratio (HR) = 0.55). In addition, updated analysis in this group of patients revealed a new potential benefit associated with Oncophage treatment: for intermediate-risk patients there was a trend towards improved overall survival, the study's secondary endpoint. Furthermore, the positive overall survival trend observed to date correlates with the RFS improvement demonstrated in previous analyses. This is the largest, randomized Phase 3 kidney cancer trial ever completed in the adjuvant treatment setting.

Christopher G. Wood, MD, associate professor of urology at M. D. Anderson Cancer Center in Houston, presented the Phase 3 end-of-study results at the annual meeting of the American Urological Association (AUA; abstract #633).

"These results continue to underscore the significant potential benefit of Oncophage in a well-defined, clinically and biologically relevant subset of patients who are the most appropriate candidates for cancer vaccines," said Dr. Wood. "In addition, there are currently no approved therapies for these patients, which represent a growing and significant population due to increased use of early detection techniques."

"We are particularly encouraged to see that the clinically significant trend observed from our earlier analysis has been strengthened by the updated data from an additional 17-month follow-up of patients," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "Although there are challenges associated with interpretation of subset analyses, the improvement demonstrated in this group of patients supports the opinion of key experts that patients with better prognostic factors are the most appropriate population to benefit from therapeutic cancer vaccines. Combined with decades of preclinical and clinical cancer vaccine data, we believe our results provide a higher level of reliability than that generally associated with outcomes from typical subset analyses."

Study Findings

Results from the investigator-reported data, which represented all data collected through the end of study (March 31, 2007), showed that:

-- Patients receiving Oncophage in the intermediate-risk population (stages I/II high-grade, III T1/2/3a low-grade) who were without disease at baseline (n = 362) demonstrated a clinically significant improvement in recurrence-free survival of approximately 45 percent (P less than 0.01; HR = 0.55). This patient population is defined by the Eastern Cooperative Oncology Group (ECOG) as at intermediate risk for disease recurrence*. Although the median survival has not yet been reached, results from the 25th percentile indicate that recurrence-free survival was extended by approximately 1.8 years in the Oncophage arm.

-- Analysis of overall survival showed improvement associated with Oncophage in the intermediate-risk population. As of data cut-off on January 2, 2006, one additional patient had died in the Oncophage arm versus 13 patients in the observation arm. This now brings the total reported deaths to 15 patients (8.2 percent) in the Oncophage arm compared with 25 deaths (14.0 percent) in the observation arm. The overall survival data are still immature due to the small number of deaths that have occurred to date; patients will continue to be monitored for survival through a global patient registry.

-- Among all eligible patients (intermediate- and high-risk patients without baseline disease; n = 604), Oncophage was associated with an 11.4 percent improvement in recurrence-free survival, which was not statistically significant (HR = 0.89).

-- There was also a promising trend for overall survival associated with Oncophage in the eligible patient population (n = 604). As of data cut-off on January 2, 2006, 24 additional deaths have been reported, with six in the Oncophage arm and 18 in the observation arm, bringing the total to 37 (12.3 percent) and 40 (13.2 percent) deaths, respectively.

-- Adverse events reported during the trial were generally mild and expected. The more frequently reported adverse events were mainly constitutional in nature or related to the actual injection.

The company is working with study investigators to publish the final findings in a peer-reviewed medical journal.

Antigenics To Continue To Follow Patients for Recurrence-Free Survival and Overall Survival Through a Global Patient Registry

A global patient registry is being launched to continue collecting data on all patients from the trial for recurrence-free survival and overall survival. The registry, which is expected to provide additional data on the effectiveness of Oncophage, will follow patients for an additional three years from closure of the initial trial, providing more than five years' worth of data collection from the last patient enrolled.

Global Registrational Strategy

Antigenics intends to seek a meeting with US Food and Drug Administration to discuss the results of the updated analyses utilizing data through March 2007 to determine whether there is an opportunity to file a biologics license application (BLA) on the basis of these results along with appropriate commitments to conduct further clinical investigations to support the efficacy of Oncophage in renal cell carcinoma. Antigenics also plans to explore the need for further clinical studies to support approval of Oncophage in ex-US markets.

Conference Call Information

Antigenics executives and Dr. Christopher Wood will host a conference call at 1:30 pm ET today. To access the live call, dial 888.271.9082 (domestic) or 706.679.7741 (international); the access code is 9197359. The call will also be webcast and will be accessible from the company's website at www.antigenics.com/webcast/. A replay will be available approximately two hours after the call through midnight ET on June 4, 2007. The replay number is 800.642.1687 (domestic) or 706.645.9291 (international), and the access code is 9197359. The replay will also be available on the company's website approximately two hours after the live call.

About Renal Cell Carcinoma

Renal cell carcinoma is the most common type of kidney cancer. The American Cancer Society estimates that there will be approximately 51,190 new cases of kidney cancer in the United States in 2007, and about 12,890 people will die from the disease. Renal cell carcinoma accounts for about 90 percent of all kidney tumors. By the time renal cell carcinoma is diagnosed in these patients, about one third of them will have developed metastatic disease.

The current standard of care for patients with nonmetastatic renal cell carcinoma consists of a nephrectomy (surgical removal of the kidney) followed by observation. There is no treatment approved by the US Food and Drug Administration for nonmetastatic renal cell carcinoma at the present time.

*Haas N. Update on targeted therapy adjuvant trials (ECOG/MRC). Paper presented at: Fifth International Symposium of the Kidney Cancer Association, 2006; Chicago.

About Antigenics

Antigenics (AGEN, Trade) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company's investigational product portfolio includes Oncophage(R) (vitespen), a patient-specific therapeutic cancer vaccine being evaluated in several indications; Aroplatin(TM) (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21, an adjuvant being evaluated by Antigenics' corporate partners in more than twenty indications, several in late-stage clinical trials. For more information, please visit antigenics.com.

This press release contains forward-looking statements, including statements regarding the potential clinical benefit of Oncophage in kidney cancer based on a subgroup analysis; the planned future data to be collected and analyzed in connection with the future development of Oncophage; and potential strategies for pursuing the registration of Oncophage. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, unfavorable data resulting from further analysis of the Oncophage Phase 3 Part 1 trial data; retention of key employees; the risk that survival data from patients that withdrew from the study or were lost to follow-up may not be available for collection or review, or that future survival data from patient monitoring may not support further development or registration of Oncophage; decisions by regulatory agencies; the ability to raise capital and finance future development of Oncophage; and the factors described under Factors That May Impact Future Results in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics' Form 10-Q as filed with the Securities and Exchange Commission on May 10, 2007. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.

SOURCE: Antigenics Inc.

Antigenics Inc. 
Media Relations: 
Sunny Uberoi, 917-443-3325 
[email protected] 
or 
Investor Relations: 
Robert Anstey, 800-962-2436 
[email protected] 

Copyright Business Wire 2007 ********************************************************************** As of Thursday, 05-17-2007 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-20-2006 for AGEN @ $5.76. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2007 Comtex News Network, Inc. All rights reserved.

[setravis]

NEW YORK, Jun 05, 2007 (BUSINESS WIRE) -- Antigenics Inc. (AGEN, Trade) today announced that GlaxoSmithKline (GSK) has launched a Phase 3 clinical trial evaluating its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in non-small cell lung cancer (NSCLC) - the largest trial ever conducted in lung cancer treatment. GSK's MAGE-A3 ASCI is delivered as a purified recombinant MAGE-A3 protein combined with GSK's proprietary adjuvant system containing Antigenics' QS-21 Stimulon(R) adjuvant, for which Antigenics will receive future milestone payments and product royalties upon successful development and commercialization. According to the World Health Organization (WHO), more than 1.3 million new cases of lung and bronchus cancer are diagnosed each year worldwide, and approximately 35 percent to 50 percent of early NSCLC expresses the MAGE-A3 antigen.(1)

"QS-21 adjuvant is a critical vaccine component for our licensees, many of whom are progressing drug candidates into late-stage development for the prevention and treatment of major diseases," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "QS-21 is a profitable product for Antigenics and today's announcement by GSK continues to underscore the substantial contribution to Antigenics' future royalty income that could be generated from our adjuvant franchise."

QS-21 is a key component included in several of GSK's proprietary adjuvant systems currently under development. Under the terms of the license and supply agreements announced in July 2006, GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for a period of at least 10 years after first commercial sale.

About QS-21 Stimulon Adjuvant

Antigenics' QS-21 Stimulon adjuvant is one of the most widely tested vaccine adjuvants under development. QS-21 has not only become a critical component in the development of preventative vaccine formulations across a wide variety of infectious diseases, but may also be essential in enabling a new generation of therapeutic vaccines to treat cancer and degenerative disorders. QS-21 is currently being evaluated in more than 20 vaccine indications, several in late-stage clinical trials by Antigenics' licensees, including GlaxoSmithKline, Elan, Acambis and Progenics. The first vaccine containing QS-21 could reach the market as early as 2009.

About Antigenics

Antigenics (AGEN, Trade) is a biotechnology company working to develop treatments for cancers and infectious diseases. The company's investigational product portfolio includes Oncophage(R) (vitespen), a patient-specific therapeutic cancer vaccine being evaluated in several indications; Aroplatin(TM) (L-NDDP), a liposomal, third-generation platinum chemotherapeutic; AG-707, a therapeutic vaccine for the treatment of genital herpes; and QS-21, an adjuvant being evaluated by Antigenics' corporate partners in more than 20 indications, several in late-stage clinical trials. For more information, please visit antigenics.com.

(1) World Health Organization- Cancer- Fact Sheet n 297 (February 2006) (www.who.int)

This press release contains forward-looking statements based on current management expectations, including statements about the future Phase 3 clinical trial in lung cancer using QS-21 by GSK, the future development of products using QS-21, and the future payment of milestone payments and royalties in connection with the development and commercialization of QS-21. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, Antigenics' dependence on its collaborative partners such as GSK to successfully develop and commercialize products containing QS-21, the scientific risk associated with the development of vaccines, the competitive risk that other sources of competitive adjuvants could become available, and difficulties or delays in manufacturing QS-21, and the risk factors described in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics' Form 10-Q as filed with the Securities and Exchange Commission on May 10, 2007. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.

SOURCE: Antigenics Inc.


Antigenics Inc. 
Media Relations 
Sunny Uberoi, 917-443-3325 
[email protected] 
or 
Investor Relations 
Robert Anstey, 800-962-2436 
[email protected] 

Copyright Business Wire 2007 ********************************************************************** As of Friday, 06-01-2007 23:59, the latest Comtex SmarTrend? Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-20-2006 for AGEN @ $5.76. As of Friday, 06-01-2007 23:59, the latest Comtex SmarTrend Alert, an automated pattern recognition system, indicated a DOWNTREND on 05-02-2007 for GSK @ $57.29. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright ? 2004-2007 Comtex News Network, Inc. All rights reserved.

[setravis]

Looking good here.......

52wk Range: 1.38 - 5.42
Volume: 1,583,031
Avg Vol (3m): 1,075,630

Technicals
Close Above the 50-day MA
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
12.70%above 13-day MA
13.77%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $129.41 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2007
Last Analyst Rating: Sell